Genetic profiling could help tailor hormone therapy for prostate cancer after surgery
A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.
A recent analysis of the NRG-RTOG 0534 SPPORT clinical trial found that adding short-term androgen deprivation therapy (STADT) to salvage radiation therapy may benefit patients with a specific subtype of prostate cancer called Luminal B (LumB). The study, presented at the 2026 American Society for Radiation Oncology Annual Meeting, suggests that molecular testing could help personalize treatment for prostate cancer patients, identifying those who may benefit from more intensive hormone therapy while sparing others from unnecessary treatment and potential side effects.
Prostate tissue from 709 patients was analyzed using the PAM50 genomic classifier, which determined whether tumors were LumB or non-LumB. Men with LumB tumors had a higher risk of disease progression and metastasis, and adding STADT, with or without pelvic lymph-node radiation, resulted in a greater benefit in freedom from progression and metastasis-free survival compared to non-LumB tumors.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
